About Us

Trillium Therapeutics Inc. is an immuno-oncology company developing innovative therapies for the treatment of cancer. Our lead program SIRPαFc is an antibody-like fusion protein that blocks the activity of CD47, a molecule that allows tumor cells to escape destruction by the immune system.

More >
TSX: TRIL Last trade 6.09 -0.02 Change -0.33% Volume 17,046 January 31, 2017
NASDAQ: TRIL Last trade 6.30 +0.00 Change +0% Volume 37,800 March 27, 2017

Management
Team

, Dr. , Niclas Stiernholm , , President and
Chief Executive Officer

Dr. Stiernholm's primary responsibilities include overseeing the company's strategic direction, executing business development plans and ensuring that our scientific programs are properly funded and advance according to schedule. Dr. Stiernholm became our President and Chief Executive Officer on our merger with the private company Trillium Therapeutics in April 2013. He joined Trillium from YM BioSciences where he was Executive Vice President and Chief Scientific Officer. While there, he played a significant role in the success of their Initial Public Offering (IPO) in 2002. Dr. Stiernholm began his industry career as a member of Allelix Biopharmaceuticals' business development office. He currently serves on the boards of AvidBiologics and Vasomune Therapeutics. He received his Ph.D. in immunology from the University of Toronto, where he also completed his postdoctoral training.

Expand

, Dr. , Bob Uger , , Chief Scientific Officer

Chief Scientific Officer
Expand

, Dr. Eric Sievers , , Chief Medical Officer

Dr. Sievers is responsible for the company’s overall clinical strategy and its clinical development programs. Previously, he served in several senior roles at Seattle Genetics, most recently as Senior Vice President, Clinical Development. From 2003 to 2006, Dr. Sievers served as Medical Director at Zymogenetics supervising the oncology development of interleukin-21 and atacicept. He performed his training in pediatric hematology and oncology at the University of Washington and the Fred Hutchinson Cancer Research Center, and served on the faculty of both institutions for more than a decade. Dr. Sievers received both a B.A. in Biology and an M.D. from Brown University.

Expand

, Mr. , James Parsons , , Chief Financial Officer

Mr. Parsons is responsible for financial and risk management, investor relations, corporate governance and administration. He has an extensive background in the life sciences industry and over 25 years of financial management experience. His past involvement in biotechnology includes roles with Amorfix Life Sciences Ltd, DiaMedica Inc, Trillium Therapeutics Inc and YM BioSciences Inc. Mr. Parsons serves on the board of Sernova Corp where he chairs the audit committee. He has a Master of Accounting degree from the University of Waterloo and is a Chartered Professional Accountant and Chartered Accountant.

Expand

, Dr. , Penka Petrova , , Chief Development Officer

Dr. Petrova is responsible for managing the company's formal drug development efforts, including all outsourced activities to contract manufacturers and contract research organizations. In addition, she continues to serve as the Head of TTI's cell biology group and oversees all of our in vivo studies. Dr. Petrova was previously Director, Drug Development at Trillium Therapeutics (private company). She joined Trillium from Prescient Neuropharma in 2003, where she held a Research Scientist position and was involved in identifying and characterizing novel proteins involved in neuroprotection. Dr. Petrova received her Ph.D. in Microbiology from Saarland University in Saarbruecken, Germany, where she also conducted her postdoctoral studies.

Expand

, Dr. , Malik Slassi , , Senior Vice President,
Discovery Research

Dr. Slassi was the Founder, President and Chief Scientific Officer of Fluorinov Pharma Inc. acquired by Trillium in January 2016. Dr. Slassi has over 25 years of experience in the successful identification of small molecule drug candidates across multiple therapeutic areas including Oncology, Neurology and Gastro-intestinal. Prior to founding Fluorinov, Dr. Slassi was Director and Vice President of Medicinal Chemistry, Manufacturing & Drug Development at NPS Pharmaceuticals and Cascade Therapeutics, respectively and earlier he held management and scientific positions at Allelix Biopharmaceuticals Inc., Boehringer Ingelheim Research Inc., and Rhône Poulenc. During his career he has been involved in numerous multinational R&D collaborations including with Hoechst AG (Sanofi-Aventis), AstraZeneca, Johnson & Johnson, Forest Laboratories, GlaxoSmithKline, and Memory Pharmaceuticals. For seven years, he served on the steering committee for the multinational collaboration on the metabotropic Glutamate Receptors (mGluRs) program between NPS and AstraZeneca. Dr. Slassi has a strong track record of drug development with over 16 drug candidates advanced into late-stage preclinical and clinical development. He is an inventor with over 130 issued and published patents and patent applications, and author of more than 65 scientific and review articles published in international peer reviewed journals. Dr. Slassi holds a Ph.D. in chemistry from the University of Claude Bernard, Lyon, France and completed his postdoctoral work in the Chemistry Department at the University of Montreal, Canada.

Expand

, Mr. , Scott Duncan , , Director of Intellectual Property

Mr. Duncan is recognized for the quality of his patent consulting services which he has provided for the past 12 years to a diverse range of biotechnology companies since he built and managed Canada’s largest biotech patent estate during his tenure with Allelix, one of Canada's initial biotech companies that was acquired by NPS Pharmaceuticals. His responsibilities within that role included the development of patent assets relating to transgenic crops, medicinal chemistry, protein drugs and expression systems, and in vitro diagnostics. Mr. Duncan has been a registered patent agent since 1986, when he qualified magna cum laude while working at a Toronto firm specializing in intellectual property.

Expand
More > More > More >

Board
of Directors

, Dr. , Calvin R. Stiller , , Chair

Dr. Calvin R. Stiller of London, Ontario is a Member of the Order of Ontario and Officer of the Order of Canada, was the recipient of the Canada Gairdner Wightman Award in 2011 (awarded to a Canadian who has demonstrated outstanding leadership in medicine and medical science) and was inducted into the Canadian Medical Hall of Fame in 2010. Dr. Stiller is Chair Emeritus of the Ontario Institute for Cancer Research, the former chair of Genome Canada and is Professor Emeritus in the Department of Medicine at the University of Western Ontario. Dr. Stiller founded the J. Allyn Taylor International Prize in Medicine, co-founded MaRS, was the Chair of the Ontario Research and Development Challenge Fund Board and was the co-founder of four venture capital funds of over $500 million. He serves on the boards of a number of private and public companies, was founding Chair of Trillium Therapeutics (private company) and was chair of VerioTherapeutics, a Canadian stem cell company that was acquired in 2010 by Fate Corporation, a California - based regeneration company. Together with Robert Klein (the founder of the California Institute of Regenerative Medicine, a state agency responsible for granting approximately $3 billion in stem cell research funding), he co-founded the Cancer Stem Cell Initiative, a Canada-California consortium that has been productive in the search for and identification of cancer stem cells. He serves on the board of Revera Corporation, one of the nation's largest seniors' accommodation, health and long-term care and services companies.

Expand

, Mr. , Luke Beshar ,

Luke Beshar served as Executive Vice President and Chief Financial Officer of NPS Pharmaceuticals from 2007 to 2015. In this role he was responsible for financial management, investor relations, information technology, technical operations, supply-chain management, facilities, project management, contracts & outsourcing and stategic and alliance management. Mr. Beshar has utilized his 30 years of experience and strategic and financial expertise to help transform NPS into a global biopharmaceutical company that is bringing innovative therapies to patients with rare diseases around the world. Under his financial leadership, NPS secured approximately $400 million of capital and its market capitalization increased from $180 million to more than $3 billion. Prior to joining NPS, Mr. Beshar served as Executive Vice President and Chief Financial Officer of Cambrex Corporation, a global life sciences company. At Cambrex, his accomplishments included raising approximately $600 million of new capital, building a high performance global finance team, and leading a process of evaluating strategic alernatives, which resulted in the sale of non-strategic operations for $460 million and an $11 per share special dividend to shareholders. Mr. Beshar began his career with Arthur Andersen & Co. and is a certified public accountant. He obtained his bachelor's degree in Accounting and Finance from Michigan State University and is a graduate of The Executive Program at the Darden Graduate School of Business at the University of Virgina.

Expand

, Dr. , Henry Friesen ,

Dr. Friesen, was the President of the Canadian Government's Medical Research Council, and the architect and lead champion for the creation the Canadian Institutes for Health Research, President of the National Cancer Institute of Canada and President of the Canadian Society for Clinical Investigation. He is the Past Founding Chair of Genome Canada. A Fellow of the Royal Society of Canada, Dr. Friesen was named a Companion of the Order of Canada and was inducted into the Canadian Medical Hall of Fame and the Order of Manitoba. He was also awarded the Gairdner Foundation Wightman Award; the McLaughlin Medal of the Royal Society of Canada; and the Koch Medal: the highest award of the Endocrine Society. He was presented with the Frederic Newton Gisborne Starr Award by the Canadian Medical Association, the association's highest award, in 2006. Dr. Friesen also holds eight Honorary Doctorates from Canadian universities.

Expand

, Dr. , Robert L. Kirkman ,

Dr. Kirkman served as President and Chief Executive Officer of Oncothyreon from September 2006 until his retirement in January 2016. From 2005 to 2006, he was acting President and Chief Executive Officer of Xcyte Therapies, which concluded a merger with Cyclacel Pharmaceuticals, both development-stage biopharmaceutical companies, in March of 2006. From 2004 to 2005, Dr. Kirkman was Chief Business Officer and Vice President of Xcyte. From 1998 to 2003, Dr. Kirkman was Vice President, Business Development and Corporate Communications of Protein Design Labs, a biopharmaceutical company. Dr. Kirkman holds a M.D. degree from Harvard Medical School and a B.A. in economics from Yale University.

Expand

, Dr. , Michael Moore ,

Dr. Moore was the Founder Chair of MISSION Therapeutics Limited, a UK drug discovery company targeting deubiquitinating enzymes for multiple disease indications. He also holds non-executive positions with UK biopharmaceutical companies including PsiOxus Therapeutics Limited, of which he was Founding Chairman, and Chronos Therapeutics Limited. From 2004-2013, Dr. Moore was non-executive Chair of Trillium Therapeutics Inc. (private) and from 2003-2008 Chief Executive Officer of Plramed Limited, a UK-based biotechnology company targeting the PI 3-kinase superfamily, which was acquired by Roche in 2008. Prior to Plramed, Dr. Moore held progressive positions at Xenova Group plc (1988-2003), including Research Director and Chief Scientific Officer. Dr. Moore’s academic career included a tenured appointment at the Paterson Institute for Cancer Research (1980) and the University of Manchester Medical School where he was Honorary Reader in immunology and oncology (1986). Dr. Moore received Ph.D. and D.Sc. degrees from the University of Nottingham (a member of the Russell Group).

Expand

, Dr. , Thomas Reynolds ,

Dr. Thomas Reynolds served as Chief Medical Officer of Seattle Genetics from March 2007 until his retirement in February 2013. While at Seattle Genetics, he was responsible for building and leading an integrated clinical development, regulatory and medical affairs organization, highlighted by the development and approval of ADCETRIS. From 2002 to 2007, Dr. Reynolds served at ZymoGenetics (acquired by Bristol-Myers Squibb in 2010), most recently as Vice President, Medical Affairs, where he oversaw the clinical development and regulatory filing of RECOTHROM. Previously, he was Vice President, Clinical Affairs at Targeted Genetics, and before that he was at Somatix Therapy (acquired by Cell Genesys in 1997). Dr. Reynolds received his M.D. and Ph.D. in Biophysics from Stanford University and a B.A. in Chemistry from Dartmouth College.

Expand

, Dr. , Niclas Stiernholm ,

Dr. Stiernholm's primary responsibilities include overseeing the company's strategic direction, executing business development plans and ensuring that our scientific programs are properly funded and advance according to schedule. Dr. Stiernholm became our President and Chief Executive Officer on our merger with the private company Trillium Therapeutics in April 2013. He joined Trillium from YM BioSciences where he was Executive Vice President and Chief Scientific Officer. While there, he played a significant role in the success of their Initial Public Offering (IPO) in 2002. Dr. Stiernholm began his industry career as a member of Allelix Biopharmaceuticals' business development office. He currently serves on the boards of AvidBiologics and Vasomune Therapeutics. He received his Ph.D. in immunology from the University of Toronto, where he also completed his postdoctoral training.

Expand
More > More > More >

Scientific Advisory Board

, Dr. , John E. Dick ,

Dr. Dick is currently Professor of Molecular Genetics at the University of Toronto and a Senior Scientist of the University Health Network in the Research Institutes of the Toronto General and Princess Margaret Hospitals and the McEwen Centre for Regenerative Medicine. He is also Director of the Program in Cancer Stem Cells at the Ontario Institute of Cancer Research (OICR). Dr. Dick’s contributions to the fields of molecular haematology, stem cell biology and oncology have been recognized by numerous prestigious awards including the Clifford Prize for Cancer Research (2009) from Australia, the Robert L. Noble Prize from National Cancer Institute of Canada (2000) and the Diamond Jubilee Award (2007) (with Drs. J.E. Till and E.A. McCulloch) from the National Cancer Institute of Canada. Dr. Dick was elected to the Royal Society of Canada in 2004. Dr. Dick's research has focused on understanding normal and leukemic human stem cells. This research developed a system for transplanting normal and leukemic human stem cells into immune-deficient mice; an assay that has revolutionized the study of human hematopoiesis. His group characterized many of the properties of normal repopulating cells with this assay system. His lab also established that only a small proportion of human leukemic cells were capable of initiating human leukemia within the immune-deficient mice. Purifiying these leukemia-initiating cells provided direct evidence for the cancer stem cell hypothesis.

Expand

, Dr. , Aaron Schimmer ,

Dr. Schimmer is a staff physician in the department of Hematology/Oncology at Princess Margaret Cancer Centre, a senior scientist at Ontario Cancer Institute and the head of Experimental Hematology at the University of Toronto. Dr. Schimmer is developing novel therapeutics for the treatment of acute leukemia. Dr. Schimmer is the author of over 135 papers, and is the inventor on over 20 patents and patent applications. He has advanced three drugs with novel mechanisms of action from his lab into clinical trials for patients with acute leukemia. He has received over 30 awards and honours for academic achievement including an award from the Ontario Ministry of Research and Innovation for the best young scientists. In 2007, Dr. Schimmer was named one of Canada's Top 40 Under 40. Dr. Schimmer received the 2012 Till & McCulloch Award, presented each year by the Stem Cell Network in recognition of the year's most influential peer-reviewed article by a researcher in Canada. He also received the 2013 Bernard and Francine Dorval prize, which is awarded by the Canadian Cancer Society to a promising investigator who began their independent research within the previous 10 years and who has made outstanding contributions to basic biomedical research.

Expand
More > More > More >

EMAIL ALERTS

Email Address: *
First Name:
Mailing Lists




 
Enter the code shown above.

Powered By Q4 Inc. 4.4.0.12